newsfilter
← Latest News
Business Wire·

Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

- FORTRESS Study Analysis Reveals Fibromyalgia Patients New to Research Demonstrate Significant IMC-1 Pain Reduction Treatment Benefits - - Company Believes FORTRESS Safety Data Supports Phase 3 Development, Requesting